Table 1.
General characteristics of patients and onset of dapsone ADRs (N=18)
| Variables | Values |
|---|---|
| Age range | 11–68 years |
| Sex (n) | Male: 10, female: 8 |
| Dose and duration of MDT for adults (WHO guidelines for multibacillary type) | Rifampicin: 600 mg once a month, |
| Clofazimine: 300 mg once a month and 50 mg daily | |
| Dapsone: 100 mg daily for 12 months | |
| Dose and duration of MDT for adults (WHO guidelines for paucibacillary type) | Rifampicin: 600 mg once a month |
| Dapsone: 100 mg daily for 6 months | |
| Dose and duration of MDT for children (aged 10–14 years: WHO guidelines for multibacillary type) | Rifampicin: 450 mg once a month |
| Clofazimine: 150 mg once a month and 50 mg every other day | |
| Dapsone: 50 mg daily for 12 months | |
| Dose and duration of MDT for children (aged 10–14 years: WHO guidelines for paucibacillary type) | Rifampicin: 450 mg once a month |
| Dapsone: 50 mg daily for 6 months | |
| Onset of symptoms of dapsone ADRs | 3–21 weeks |
Abbreviations: ADR, adverse drug reaction; MDT, multidrug therapy; WHO, World Health Organization.